Abbott India Ltd banner
A

Abbott India Ltd
NSE:ABBOTINDIA

Watchlist Manager
Abbott India Ltd
NSE:ABBOTINDIA
Watchlist
Price: 25 305 INR -0.67%
Market Cap: ₹537.7B

P/B

13.4
Current
15%
Cheaper
vs 3-y average of 15.8

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
13.4
=
Market Cap
₹555.7B
/
Total Equity
₹40.1B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
13.4
=
Market Cap
₹555.7B
/
Total Equity
₹40.1B

Valuation Scenarios

Abbott India Ltd is trading below its 3-year average

If P/B returns to its 3-Year Average (15.8), the stock would be worth ₹29 876.64 (18% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-76%
Maximum Upside
+18%
Average Downside
29%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 13.4 ₹25 305
0%
3-Year Average 15.8 ₹29 876.64
+18%
5-Year Average 15.4 ₹28 994.99
+15%
Industry Average 3.6 ₹6 713.49
-73%
Country Average 3.3 ₹6 134.56
-76%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
IN
Abbott India Ltd
NSE:ABBOTINDIA
541.3B INR 13.4 35.3
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 30.3 39
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 6.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 7.7 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 5.8 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 5.9 19.5
US
Merck & Co Inc
NYSE:MRK
274.6B USD 5.2 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD -58.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 5.9 11.1
US
Pfizer Inc
NYSE:PFE
149.3B USD 1.7 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 6.3 16.4
P/E Multiple
Earnings Growth PEG
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average P/E: 22.9
35.3
12%
2.9
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.5
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1

Market Distribution

Higher than 92% of companies in India
Percentile
92nd
Based on 2 820 companies
92nd percentile
13.4
Low
0 — 2.1
Typical Range
2.1 — 5.5
High
5.5 —
Distribution Statistics
India
Min 0
30th Percentile 2.1
Median 3.3
70th Percentile 5.5
Max 4 699.1

Abbott India Ltd
Glance View

Abbott India Ltd., a subsidiary of the global healthcare conglomerate Abbott Laboratories, operates as a key player in India’s pharmaceutical landscape. Nestled in the vibrant, ever-evolving Indian market, Abbott India has carved a niche for itself with a strategic focus on both innovation and localization. Its operations span the development, manufacture, and sale of a wide array of pharmaceutical products. By leveraging Abbott's global expertise and its deep understanding of local market dynamics, the company designs solutions catered to the unique health challenges faced by Indian consumers. Their product portfolio includes a diverse range of proprietary medicines, nutrition products, diagnostics, and branded generics, which address therapeutic areas like cardiology, women's health, gastroenterology, and metabolic disorders. Abbott India’s revenue engine primarily hinges on its extensive distribution networks and its substantial investments in research and development aimed at optimizing treatment paradigms. The company employs a customer-centric approach, working closely with healthcare professionals to ensure the accessibility of its medications across the country. By aligning its operations with the latest trends in healthcare needs and regulatory requirements, Abbott India ensures it remains at the forefront of serving its consumers efficiently. Its commitment to quality and continuous product improvement not only strengthens its market position but also fuels its growth trajectory in the Indian pharmaceutical sector, making it a formidable entity poised for sustained success in a dynamic industry.

ABBOTINDIA Intrinsic Value
18 077.03 INR
Overvaluation 29%
Intrinsic Value
Price ₹25 305
A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett